Merck’s Phase 3 KEYNOTE-B96 Trial Meets PFS Goal in Platinum-Resistant Ovarian Cancer

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today reported that its Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) has met its primary endpoint, showing a statistically significant improvement in progression-free survival (PFS) for patients with platinum-resistant recurrent…

Read MoreMerck’s Phase 3 KEYNOTE-B96 Trial Meets PFS Goal in Platinum-Resistant Ovarian Cancer

Meridian Health Plan Partners with Illinois Farmers Markets to Address Food Insecurity

Meridian, a provider of government-sponsored managed care services and a Centene company (NYSE: CNC), announced today the continuation and expansion of its health equity efforts through partnerships with farmers markets across central and southern Illinois in 2025. This initiative aims…

Read MoreMeridian Health Plan Partners with Illinois Farmers Markets to Address Food Insecurity